Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) | First-line HER2-positive gastroesophageal adenocarcinoma (GEA) | Phase 3 | Data Released | Intravenous infusion | Oncology |
| Jazz Pharmaceuticals plc | EPIDIOLEX (cannabidiol) | Epilepsy with Myoclonic-Atonic Seizures (EMAS) / Doose syndrome | Phase 3 | Ongoing | Oral | Neurology |
| Jazz Pharmaceuticals plc | Lurbinectedin | Small cell lung cancer (SCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Jazz Pharmaceuticals plc | EPIDIOLEX (cannabidiol) | Rett syndrome | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Jazz Pharmaceuticals plc | SATIVEX (nabiximols) | Spasticity due multiple sclerosis | Phase 3 | Trial Discontinued | Oral mucosal | Neurology |
| Jazz Pharmaceuticals plc | Defibrotide | VOD in high-risk patients following hematopoietic stem cell transplantation | Phase 3 | Trial Discontinued | Intravenous | Hematology |
| Jazz Pharmaceuticals plc | JZP-110 | Excessive sleepiness associated with obstructive sleep apnea | Phase 3 | Trial Completed | oral | Neurology |
| Jazz Pharmaceuticals plc | SATIVEX (nabiximols) - (RELEASE MSS1) | Multiple sclerosis (MS)-related spasticity | Phase 3 | Data Released | oromucosal | Neurology |
